BridgeBio Pharma (FRA:2CL) LT-Debt-to-Total-Asset : 2.59 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BridgeBio Pharma's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 2.59.

BridgeBio Pharma's long-term debt to total assets ratio declined from Sep. 2023 (2.64) to Sep. 2024 (2.59). It may suggest that BridgeBio Pharma is progressively becoming less dependent on debt to grow their business.

BridgeBio Pharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for BridgeBio Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma LT-Debt-to-Total-Asset Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.15

0.70

1.70

2.76

3.18

BridgeBio Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															2.64	3.18	2.03	2.17	2.59

BridgeBio Pharma LT-Debt-to-Total-Asset Calculation

BridgeBio Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1591.646	/	501.03
	=	3.18

BridgeBio Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	1554.359	/	599.144
	=	2.59

BridgeBio Pharma (FRA:2CL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BridgeBio Pharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

BBIO:USA

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

BridgeBio Pharma Headlines

No Headlines